| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
An αIIbβ3 monoclonal antibody traps a semiextended conformation and allosterically inhibits large ligand binding
|
Wang, Lu
|
|
|
8 |
16 |
p. 4398-4409
|
artikel
|
| 2 |
Associations between acute and chronic graft-versus-host disease
|
Tamaki, Masaharu
|
|
|
8 |
16 |
p. 4250-4261
|
artikel
|
| 3 |
Beyond BCMA: newer immune targets in myeloma
|
Tan, Melinda S. Y.
|
|
|
8 |
16 |
p. 4433-4446
|
artikel
|
| 4 |
CAR T-cell toxicities: from bedside to bench, how novel toxicities inform laboratory investigations
|
Perna, Fabiana
|
|
|
8 |
16 |
p. 4348-4358
|
artikel
|
| 5 |
CD163+ macrophages in mantle cell lymphoma induce activation of prosurvival pathways and immune suppression
|
de Matos Rodrigues, Joana
|
|
|
8 |
16 |
p. 4370-4385
|
artikel
|
| 6 |
Dalby A, Mezzano D, Rivera J, et al. Introduction of an ancient founder glycoprotein VI mutation into the Chilean population. Blood Adv. 2022;6(22):5866-5869.
|
|
|
|
8 |
16 |
p. 4397
|
artikel
|
| 7 |
Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study
|
Jain, Tania
|
|
|
8 |
16 |
p. 4281-4293
|
artikel
|
| 8 |
Doubling down on PK activation for sickle cell disease
|
Wilson, Samuel R.
|
|
|
8 |
16 |
p. 4457-4458
|
artikel
|
| 9 |
Ending endless follow-up for low-risk CLL?
|
Thompson, Philip A.
|
|
|
8 |
16 |
p. 4447-4448
|
artikel
|
| 10 |
Evaluating the impact of laboratory-based eligibility criteria by race/ethnicity in first-line clinical trials of DLBCL
|
Khurana, Arushi
|
|
|
8 |
16 |
p. 4414-4422
|
artikel
|
| 11 |
Global prevalence of hereditary thrombotic thrombocytopenic purpura determined by genetic analysis
|
Seidizadeh, Omid
|
|
|
8 |
16 |
p. 4386-4396
|
artikel
|
| 12 |
High-dose alemtuzumab and cyclosporine vs tacrolimus, methotrexate, and sirolimus for chronic graft-versus-host disease prevention
|
Holtzman, Noa G.
|
|
|
8 |
16 |
p. 4294-4310
|
artikel
|
| 13 |
IgG testing, immunoglobulin replacement therapy, and infection outcomes in patients with CLL or NHL: real-world evidence
|
Soumerai, Jacob D.
|
|
|
8 |
16 |
p. 4239-4249
|
artikel
|
| 14 |
Interleukin-1β, JAK2V617F mutation and inflammation in MPNs
|
Hermouet, Sylvie
|
|
|
8 |
16 |
p. 4344-4347
|
artikel
|
| 15 |
It is feasible and safe to stop specialized follow-up of asymptomatic lower-risk chronic lymphocytic leukemia
|
Brieghel, Christian
|
|
|
8 |
16 |
p. 4449-4456
|
artikel
|
| 16 |
Low frequency of Vγ9Vδ2 T cells predicts poor survival in newly diagnosed acute myeloid leukemia
|
Le Floch, Anne-Charlotte
|
|
|
8 |
16 |
p. 4262-4275
|
artikel
|
| 17 |
Maternal red blood cell alloimmunization prevalence in the United States
|
Sugrue, Ronan P.
|
|
|
8 |
16 |
p. 4311-4319
|
artikel
|
| 18 |
Metformin for MPN: teaching an old drug new tricks
|
Lee, Michelle H.
|
|
|
8 |
16 |
p. 4476-4477
|
artikel
|
| 19 |
Metformin use and risk of myeloproliferative neoplasms: a Danish population–based case-control study
|
Kristensen, Daniel Tuyet
|
|
|
8 |
16 |
p. 4478-4485
|
artikel
|
| 20 |
Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease
|
Saraf, Santosh L.
|
|
|
8 |
16 |
p. 4459-4475
|
artikel
|
| 21 |
Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention
|
Furqan, Fateeha
|
|
|
8 |
16 |
p. 4320-4329
|
artikel
|
| 22 |
Platelet proteomic profiling reveals potential mediators of immunothrombosis and proteostasis in myeloproliferative neoplasms
|
Kelliher, Sarah
|
|
|
8 |
16 |
p. 4276-4280
|
artikel
|
| 23 |
Prophylactic exchange transfusion in sickle cell disease pregnancy: a TAPS2 feasibility randomized controlled trial
|
Oteng-Ntim, Eugene
|
|
|
8 |
16 |
p. 4359-4369
|
artikel
|
| 24 |
Risk-adapted MRD-directed therapy for young adults with acute myeloid leukemia: 6-year update of the GIMEMA AML1310 trial
|
Venditti, Adriano
|
|
|
8 |
16 |
p. 4410-4413
|
artikel
|
| 25 |
Risk of transformation by frontline management in follicular and marginal zone lymphomas: a US population–based analysis
|
Florindez, Jorge A.
|
|
|
8 |
16 |
p. 4423-4432
|
artikel
|
| 26 |
Tumor microenvironment of Burkitt lymphoma: different immune signatures with different clinical behavior
|
Siciliano, Maria Chiara
|
|
|
8 |
16 |
p. 4330-4343
|
artikel
|
Tijdschrift beschrijving